Regulatory Replimune gets early August decision date for twice-rejected melanoma drug BioSpaceReplimune's resubmission for RP1 for melanoma comes after the departures of FDA leaders in place at the time of the drug's first two rejections.OncologyRead full story pharminent June 26, 2026 (Last updated: June 26, 2026) BioSpace Replimune’s resubmission for RP1 for melanoma comes after the departures of FDA leaders in place at the time of the drug’s first two rejections. Oncology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Moderna looks out to R&D ‘horizons’ as 2028 break-even goal loomsNext: Moderna Maps R&D ‘Horizons’ as 2028 Break-Even Goal Looms Related Stories Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA pharminent July 31, 2026 Regulatory Outlook finally claims FDA approval for AMD drug pharminent July 27, 2026 Regulatory Outlook Therapeutics wins FDA approval for Lytenava in wet AMD pharminent July 27, 2026
